• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis : Comment on "Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis".

作者信息

Noe S, Jaeger H, Wolf E

机构信息

MVZ Karlsplatz, HIV Research and Clinical Care Center, 80335, Munich, Germany.

MUC Research, 80335, Munich, Germany.

出版信息

Osteoporos Int. 2019 Aug;30(8):1705-1706. doi: 10.1007/s00198-019-05024-4. Epub 2019 May 29.

DOI:10.1007/s00198-019-05024-4
PMID:31143992
Abstract
摘要

相似文献

1
Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis : Comment on "Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis".处于骨质疏松风险或患有骨质疏松的HIV感染者的抗逆转录病毒治疗选择：对《HIV感染者骨脆性的诊断、预防和治疗：瑞士骨质疏松症防治协会的立场声明》的评论
Osteoporos Int. 2019 Aug;30(8):1705-1706. doi: 10.1007/s00198-019-05024-4. Epub 2019 May 29.
2
Reply to "Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis. Comment on: Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis" by S. Noe, H. Jaeger, E. Wolf.对S. Noe、H. Jaeger、E. Wolf所著《处于骨质疏松风险或患有骨质疏松的HIV感染者的抗逆转录病毒治疗选择。评论：HIV感染者骨脆性的诊断、预防和治疗：瑞士骨质疏松症防治协会的立场声明》的回复
Osteoporos Int. 2019 Aug;30(8):1707. doi: 10.1007/s00198-019-05025-3. Epub 2019 May 29.
3
Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.诊断、预防和治疗 HIV 感染者的骨脆弱症：瑞士抗骨质疏松协会立场声明。
Osteoporos Int. 2019 May;30(5):1125-1135. doi: 10.1007/s00198-018-4794-0. Epub 2019 Jan 2.
4
Bone loss in HIV: a contemporary review.HIV感染中的骨质流失：当代综述
Curr Opin Endocrinol Diabetes Obes. 2015 Dec;22(6):446-51. doi: 10.1097/MED.0000000000000200.
5
Emerging bone problems in patients infected with human immunodeficiency virus.感染人类免疫缺陷病毒患者中出现的骨骼问题。
Clin Infect Dis. 2003 Apr 1;36(Suppl 2):S101-5. doi: 10.1086/367566.
6
Do people with HIV infection have a higher risk of fracture compared with those without HIV infection?与未感染艾滋病毒的人相比，感染艾滋病毒的人骨折风险更高吗？
Curr Opin HIV AIDS. 2016 May;11(3):301-5. doi: 10.1097/COH.0000000000000249.
7
HIV infection, bone metabolism, and fractures.HIV感染、骨代谢与骨折
Arq Bras Endocrinol Metabol. 2014 Jul;58(5):478-83. doi: 10.1590/0004-2730000003323.
8
Protecting bone in long-term HIV positive patients receiving antiretrovirals.在接受抗逆转录病毒治疗的长期HIV阳性患者中保护骨骼
Expert Rev Anti Infect Ther. 2016 Jun;14(6):587-99. doi: 10.1080/14787210.2016.1184570.
9
Hypogonadism and bone health in men with HIV.男性 HIV 感染者的性腺功能减退症与骨骼健康。
Lancet HIV. 2020 Nov;7(11):e782-e790. doi: 10.1016/S2352-3018(20)30236-8.
10
[Multifactorial relations between HIV, HAART and bone metabolism].[人类免疫缺陷病毒、高效抗逆转录病毒治疗与骨代谢之间的多因素关系]
Infez Med. 2006 Sep;14(3):117-24.

引用本文的文献

1
Reply to "Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis. Comment on: Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis" by S. Noe, H. Jaeger, E. Wolf.对S. Noe、H. Jaeger、E. Wolf所著《处于骨质疏松风险或患有骨质疏松的HIV感染者的抗逆转录病毒治疗选择。评论：HIV感染者骨脆性的诊断、预防和治疗：瑞士骨质疏松症防治协会的立场声明》的回复
Osteoporos Int. 2019 Aug;30(8):1707. doi: 10.1007/s00198-019-05025-3. Epub 2019 May 29.

本文引用的文献

1
Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.诊断、预防和治疗 HIV 感染者的骨脆弱症：瑞士抗骨质疏松协会立场声明。
Osteoporos Int. 2019 May;30(5):1125-1135. doi: 10.1007/s00198-018-4794-0. Epub 2019 Jan 2.
2
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.多替拉韦加拉米夫定与多替拉韦富马酸酯替诺福韦二吡呋酯和恩曲他滨在初治 HIV-1 感染的成人中的疗效比较（GEMINI-1 和 GEMINI-2）：两项多中心、双盲、随机、非劣效性、3 期临床试验的第 48 周结果。
Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9.
3
Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?丙酚替诺福韦与富马酸替诺福韦二吡呋酯：在疗效和安全性上是否存在真正差异？
J Virus Erad. 2018 Apr 1;4(2):72-79. doi: 10.1016/S2055-6640(20)30248-X.
4
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.阿扎那韦/利托那韦联合拉米夫定作为维持治疗对病毒学抑制的 HIV 感染患者：一项随机试验的 96 周结果。
J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964. doi: 10.1093/jac/dky123.
5
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.多替拉韦利匹韦林治疗成人 HIV-1 病毒学抑制维持治疗的疗效、安全性和耐受性：III 期、随机、非劣效性 SWORD-1 和 SWORD-2 研究。
Lancet. 2018 Mar 3;391(10123):839-849. doi: 10.1016/S0140-6736(17)33095-7. Epub 2018 Jan 6.
6
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.从富马酸替诺福韦二吡呋酯复方制剂转换为多替拉韦利匹韦林可改善骨健康相关参数。
AIDS. 2018 Feb 20;32(4):477-485. doi: 10.1097/QAD.0000000000001725.
7
Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.人类免疫缺陷病毒感染个体的骨密度降低：患病率及其危险因素的荟萃分析。
Osteoporos Int. 2018 Mar;29(3):595-613. doi: 10.1007/s00198-017-4305-8. Epub 2017 Nov 20.
8
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.在病毒学抑制的 HIV-1 成人患者中，48 周时从增效蛋白酶抑制剂联合恩曲他滨和替诺福韦酯转换为达芦那韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺单片复方制剂的疗效和安全性（EMERALD）：一项 3 期、随机、非劣效性试验。
Lancet HIV. 2018 Jan;5(1):e23-e34. doi: 10.1016/S2352-3018(17)30179-0. Epub 2017 Oct 6.
9
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>.恩曲他滨/丙酚替诺福韦（FTC/TAF）与恩曲他滨/富马酸替诺福韦二吡呋酯（FTC/TDF）作为病毒学抑制的成年HIV-1感染者治疗基础用药的疗效和安全性：一项随机、双盲、活性对照3期试验的第三药物亚组分析
HIV Clin Trials. 2017 May;18(3):135-140. doi: 10.1080/15284336.2017.1291867. Epub 2017 Mar 17.
10
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.简要报告：替诺福韦艾拉酚胺（TAF）与富马酸替诺福韦二吡呋酯（TDF）分别与埃替拉韦、考比司他和恩曲他滨（E/C/F）联合用于初治HIV-1感染的随机、双盲比较：第144周结果
J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):211-218. doi: 10.1097/QAI.0000000000001350.